Development, validation of a novel symptom burden scale to assess and quantify the burden experienced by people living with Idiopathic Multicentric Castleman Disease (iMCD).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Long list of candidate items for the scale (stage 1)
Timeframe: Sept 2023 - Nov 2023
Completion of interviews (stage 2)
Timeframe: Within 6 months from start (With this being a rare condition, data from all patients will be collected at various levels of treatment and time from diagnosis)
Completion of questionnaire (stage 3)
Timeframe: Within 9 months from start (With this being a rare condition, data from all patients will be collected at various levels of treatment and time from diagnosis). NB: Advisory comments noted.
Completion of follow-up questionnaire (stage 4a)
Timeframe: About 8 weeks after Stage 3 questionnaire. Note: Advisory comments noted.
Completion of interviews (stage 4b)
Timeframe: About 4 weeks after Stage 4a